Connect with us

Hi, what are you looking for?

Life

Migraine Tool Reduces Suffering

A migraine treatment breakthrough will be discussed today at the
American Academy of Neurology annual meeting. Results of an
international trial sponsored by AstraZeneca (NYSE:AZN) show that MIDAS,
an innovative, yet simple, five-question form, helps migraine patients
find appropriate medication the first time they talk to their doctor.
Without this tool, many patients suffer through a lengthy and
inefficient treatment process starting with simple analgesics and
working their way up to more potent medications when previous
medications fail.

The MIDAS questionnaire, for Migraine Disability Assessment Scale, is
designed to allow patients with severe migraine to skip simple
analgesics in the course of treatment. In the past, physicians have not
had a clinically relevant reliable tool to assess disability at the
onset of treatment, so they have started patients with a simple
analgesic, regardless of the severity of their migraine attacks.

Doctors use MIDAS to measure a sufferer’s disability and assign a score
based on answers to questions about time lost from the workplace,
housework and leisure activities. This information helps physicians to
select the most appropriate treatment plan, giving simple analgesics
like aspirin to patients with lower scores and prescribing more powerful
medications to patients with higher scores.

www.astrazeneca-us.com
www.zomig.com.

You may also like:

Business

Businesses should beware the insider threat, says a cybersecurity analyst.

Life

Moving forward on the campaign trail. Source - Justin Trudeau @JustinTrudeau Officiel du gouvernement - Canada.Justin Trudeau is facing harsh criticism from political rivals...

Business

Many people, meaning millions, are truly outraged and offended by billionaires going into space on joyrides.

Business

FIFA Women's World Cup 2019 Final - The US team receiving their champion medals. Image - Howcheng, CC SA 4.0. The US Soccer Federation...